Last reviewed · How we verify
Gardnerella Vaginalis Bacterial Vaginosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Klaron | SULFACETAMIDE | Merck & Co. | Sulfonamide Antibacterial | Dihydrofolate reductase | 1945-01-01 | |
| Sulfabenzid | SULFABENZAMIDE | Johnson & Johnson | sulfabenzamide | 1945-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Johnson & Johnson · 1 drug in Gardnerella Vaginalis Bacterial Vaginosis
- Merck & Co. · 1 drug in Gardnerella Vaginalis Bacterial Vaginosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Gardnerella Vaginalis Bacterial Vaginosis:
- Gardnerella Vaginalis Bacterial Vaginosis treatment updates — RSS
- Gardnerella Vaginalis Bacterial Vaginosis treatment updates — Atom
- Gardnerella Vaginalis Bacterial Vaginosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Gardnerella Vaginalis Bacterial Vaginosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gardnerella-vaginalis-bacterial-vaginosis. Accessed 2026-06-10.
Related
- Gardnerella Vaginalis Bacterial Vaginosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing